Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?

Insider Monkey10-01

We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472379326?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZyvYqvKxNpBWlHwzdONqtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/936769d778c202b5bc0f6633f10948f7","is_english":true,"pubTime":"2024-10-01 21:58","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2472379326","market":"us","top_or_hot":-1,"title":"Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunovant-inc-imvt-worst-performing-135825868.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-01 21:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/immunovant-inc-imvt-worst-performing-135825868.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunovant-inc-imvt-worst-performing-135825868.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/immunovant-inc-imvt-worst-performing-135825868.html","article_id":"2472379326","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZyvYqvKxNpBWlHwzdONqtQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/936769d778c202b5bc0f6633f10948f7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472379326","pubTimestamp":1727791105,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc.  ranks among the worst performing stocks to buy on the dip.Capital markets demonstrated increased volatility starting in August 2024 and continuing in September 2024. That being said, strong rallies followed numerous negative performance days. Therefore, these movements have helped keep the stocks moving in an overall positive direction. Market experts believe this is a great time to invest in equities. For those having money in cash, the current juncture provides an opportunity to put capital to work in the longer-term assets.The initial seven months of 2024 saw the broader market move forward, with only modest interruption or volatility. After a tough August start, the stocks recovered quickly, and the broader markets again ended the month in positive territory","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","VOO":"Vanguard标普500ETF","OEF":"标普100指数ETF-iShares","BK4588":"碎股","TQQQ":"纳指三倍做多ETF","BK4550":"红杉资本持仓",".IXIC":"NASDAQ Composite","PSQ":"纳指反向ETF",".SPX":"S&P 500 Index","OEX":"标普100","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","BK4581":"高盛持仓","BK4504":"桥水持仓","IVV":"标普500指数ETF","SSO":"两倍做多标普500ETF","BK4516":"特朗普概念","SH":"标普500反向ETF","QID":"纳指两倍做空ETF","IMVT":"Immunovant, Inc.","BK4187":"航天航空与国防","GD":"通用动力","SPXU":"三倍做空标普500ETF","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SQQQ":"纳指三倍做空ETF","BK4139":"生物科技","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4566":"资本集团","SPY":"标普500ETF","QLD":"纳指两倍做多ETF"},"translate_title":"Immunovant，Inc.(IMVT)是逢低买入表现最差的股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":1,"GD":1,".IXIC":0.9,"VOO":0.89,"SPY":0.89,"US6M.BOND":0.71,"US5Y.BOND":0.71,"US3Y.BOND":0.71,"US30Y.BOND":0.71,"US2Y.BOND":0.71,"US12M.BOND":0.71,"US10Y.BOND":0.71,"US7Y.BOND":0.71,"SDS":0.6,"SH":0.6,"SPXU":0.6,"PSQ":0.6,"QLD":0.6,"SQQQ":0.6,"SSO":0.6,"TQQQ":0.6,"UPRO":0.6,"US912797GW17.BOND":0.6,"US912797HE00.BOND":0.6,".SPX":0.6,"QID":0.6,"ESmain":0.6,"MNQmain":0.6,"NQmain":0.6,"IVV":0.6,"OEF":0.6,"OEX":0.6},"content_text":"We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the dip.\nCapital markets demonstrated increased volatility starting in August 2024 and continuing in September 2024. That being said, strong rallies followed numerous negative performance days. Therefore, these movements have helped keep the stocks moving in an overall positive direction. Market experts believe this is a great time to invest in equities. For those having money in cash, the current juncture provides an opportunity to put capital to work in the longer-term assets.\nWall Street experts believe that the markets are concerned about the signs of economic softness. The experts continue to assess how quickly the US Fed will respond to it through the adjustments in the interest rate policy. With the US Fed starting to cut the key policy rates, global money managers continue to figure out whether it is too late, or will the actions support the broader economy and continued corporate earnings growth. The economic environment has now been changed, with inflation falling and the job market appearing to be modestly weaker. The market experts believe that equity market leadership saw a drastic shift, with tech stocks seeing a modest, third-quarter retreat after leading the market’s surge since late 2022.\nQ3 Market Rotation and Market Drivers Moving Forward\nAs per the US Bank, a subsidiary of the U.S. Bancorp, there was a major Q3 shift that took place in the S&P 500. The bank highlighted that the once-dominant technology sectors (IT and communication services), which outpaced other sectors in 2023 and in H1 2024, gave up some gains. As a result of an easing interest rate environment, the investors decided to shift their focus. The US Bank went on to highlight that the biggest Q3 beneficiaries were real estate and utility stocks.\nMoving forward, inflation, labor market trends, business spending patterns, corporate earnings, and stock valuations are likely to dominate the broader US equity market. The US Bank mentioned that Q2 2024 earnings saw an increase of over 10% as compared to Q2 2023 earnings. Despite the challenges related to a slowing economy, the earnings expectations have not been changed. Notably, the markets continue to expect continued earnings growth through the remainder of 2024 and 2025. As per the earnings insight report by FactSet (dated September 20, 2024), for Q3 2024, the estimated (YoY) earnings growth rate for the S&P 500 stood at 4.6%. While analysts are expecting YoY earnings growth of 10.0% for CY 2024, they expect ~15.2% for CY 2025.\nAmidst Volatility, Markets Will Experience Swift Recovery\nThe initial seven months of 2024 saw the broader market move forward, with only modest interruption or volatility. After a tough August start, the stocks recovered quickly, and the broader markets again ended the month in positive territory, only to start September on a volatile note. Most of the volatility stemmed from the expectations of a series of Fed rate cuts. This can be considered as the big driver for the broader market, mainly when the economic focus pivots to labor market conditions instead of inflation threats.\nAmidst the broad-based volatility, market experts opine that large stocks were able to retain their advantage.\nIn July, there was an outperformance by the small stocks as the Russell 2000 Small-Cap Index gained over ~10%, compared to a ~1% gain for the large-cap S&P 500. This was mainly because of the prospects of Fed rate cuts, which led to the short-term shift into smaller stocks. However, the rotation to smaller-cap stocks was again sidetracked in August, with the S&P 500 again outperforming mid-cap and small-cap stocks. Over the past month, the Russell 2000 Index saw an increase of ~0.3%, while the S&P 500 Index went up by over ~2%. This demonstrates that, amidst volatility and macro-level changes, well-established stocks should be favored as they provide reasonably good entry points.\nOur methodology\nTo list the 10 Worst Performing Stocks to Buy on the Dip, we used a Finviz screener and online rankings to filter out the stocks that have fallen significantly on a YTD basis. Finally, we ranked the stocks according to their potential upside, as of September 27. We have also included the number of hedge fund holders for each stock, as of Q2 2024, which we sourced from our database of over 900 elite hedge funds.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n\nImmunovant, Inc. (NASDAQ:IMVT)\nAverage Upside Potential: 73.09%\n% Fall on a YTD Basis: ~32%\nNumber of Hedge Fund Holdings: 41 Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company, which is engaged in developing monoclonal antibodies for the treatment of autoimmune diseases. The company remains focused on autoimmune disorders targeting the FcRn mechanism of action. In the recent past, Immunovant, Inc. (NASDAQ:IMVT)’s stock price was significantly impacted as a result of several concerns. One concern that impacted the investors’ confidence the most was the competitor argenx SE’s failure in pemphigus vulgaris. This has raised questions about the addressable opportunity for the FcRn class. These factors, together with the relatively significant cash burn, have impacted the company’s stock price. On the other hand, Wall Street believes that Immunovant, Inc. (NASDAQ:IMVT) is well-placed for long-term growth as a result of its strategic growth plans. The company shifted its focus to IMVT-1402 as its lead drug candidate. The market experts believe that this is a strategic growth decision because of the drug’s potential to be best-in-class. IMVT-1402, which is an anti-FcRn candidate, should start 4-5 potentially registrational trials in the upcoming fiscal year. Recently, Immunovant, Inc. (NASDAQ:IMVT) reported positive outcomes from its Phase 2a trial of batoclimab for the treatment of Graves’ Disease (GD). Notably, the market players are optimistic about the company’s development plans for Graves’ disease, which is a large commercial unmet need. HC Wainwright reissued a “Buy” rating on the shares of Immunovant, Inc. (NASDAQ:IMVT), issuing a price objective of $51.00 on 10\nth September. As per Insider Monkey’s Q2 2024 data, 41 hedge funds were long Immunovant, Inc. (NASDAQ:IMVT).  Baron Funds, an investment management company, released its first quarter 2024 investor letter. \nHere is what the fund said: \n\n“Somewhat offsetting the above was adverse stock selection in biotechnology and health care supplies coupled with cash exposure amid favorable market conditions. Weakness in biotechnology was mainly due to disappointing performance from Rocket Pharmaceuticals, Inc. and Immunovant, Inc. (NASDAQ:IMVT), whose shares fell double digits in the period. Immunovant is focused on autoimmune disorders targeting the FcRn mechanism of action. A host of concerns weighed on Immunovant’s stock price, the most critical of which was competitor argenx SE’s failure in pemphigus vulgaris, which has raised questions about the addressable opportunity for the FcRn class. Overall, we continue to believe FcRn will command billions in revenue and that Immunovant has one of the two competitive offerings in the space. We are most optimistic about Immunovant’s development plans in Graves’ disease, a large commercial unmet need in which they currently have no competition.”\n\nOverall IMVT ranks 1st on our list of the worst performing stocks to buy on the dip. While we acknowledge the potential of IMVT as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a deeply undervalued AI stock that is more promising than IMVT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.   \nREAD NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’   \nDisclosure: None. This article is originally published on Insider Monkey.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472379326"}